Hjem
James B. Lorenss bilde

James B. Lorens

Professor
  • E-postJim.Lorens@uib.no
  • Telefon+47 55 58 67 76+47 975 57 112
  • Besøksadresse
    Jonas Lies vei 91
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with EGFR TKI and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells. Cancers. 1-24.
  • Vis forfatter(e) 2021. Axl-inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model. Journal of Cellular and Molecular Medicine. 7407-7417.
  • Vis forfatter(e) 2020. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer. 824-836.
  • Vis forfatter(e) 2020. AXL is a driver of stemness in normal mammary gland and breast cancer. iScience. 1-40.
  • Vis forfatter(e) 2020. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology. 973-999.
  • Vis forfatter(e) 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • Vis forfatter(e) 2019. Adenoviral mediated mono delivery of BMP2 is superior to the combined delivery of BMP2 and VEGFA in bone regeneration in a critical-sized rat calvarial bone defect. Bone Reports.
  • Vis forfatter(e) 2019. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. Physiological Reports. 1-20.
  • Vis forfatter(e) 2019. AXL targeting overcomes human lung cancer cell resistance to NK- And CTL-mediated cytotoxicity. Cancer immunology research. 1789-1802.
  • Vis forfatter(e) 2019. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cellular and Molecular Gastroenterology and Hepatology (CMGH).
  • Vis forfatter(e) 2018. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. Frontiers in Cell and Developmental Biology.
  • Vis forfatter(e) 2018. Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT‐β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem. 224-236.
  • Vis forfatter(e) 2018. High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia. Cell reports. 1205-1219.
  • Vis forfatter(e) 2018. A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 57-70.
  • Vis forfatter(e) 2017. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Cancer Research. 246-255.
  • Vis forfatter(e) 2017. Microsphere cytometry to interrogate microenvironment-dependent cell signaling. Integrative Biology. 123-134.
  • Vis forfatter(e) 2017. Clear cell renal cell carcinoma is linked to epithelial-to-mesenchymal transition and to fibrosis. Physiological Reports. 1-18.
  • Vis forfatter(e) 2017. Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Internal Medicine. 1774-1780.
  • Vis forfatter(e) 2017. Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. Oncoimmunology. 1-11.
  • Vis forfatter(e) 2015. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research. 3699-3705.
  • Vis forfatter(e) 2015. Vimentin-ERK signaling uncouples slug gene regulatory function. Cancer Research. 2349-2362.
  • Vis forfatter(e) 2015. The immortality two-step. Cell Cycle. 798 sider.
  • Vis forfatter(e) 2015. Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Molecular Biology of the Cell. 2698-2711.
  • Vis forfatter(e) 2015. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Disease Models and Mechanisms. 1201-1211.
  • Vis forfatter(e) 2015. A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports.
  • Vis forfatter(e) 2014. Mesenchymal stem cells induce endothelial cell quiescence and promote capillary formation. Stem Cell Research & Therapy.
  • Vis forfatter(e) 2014. In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells. Leukemia Research and Treatment.
  • Vis forfatter(e) 2014. Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets. BMC Biotechnology.
  • Vis forfatter(e) 2014. Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells . VASA. 124-131.
  • Vis forfatter(e) 2014. Automated quantification and integrative analysis of 2D and 3D mitochondrial shape and network properties. PLOS ONE.
  • Vis forfatter(e) 2014. Auswirkungen von enoxaparin und dalteparin auf die proliferation und migration humaner vaskulärer glatter muskelzellen aus einem patientenkollektiv. VASA. 124-131.
  • Vis forfatter(e) 2014. Akt1 activity regulates vessel maturation in a tissue engineering model of angiogenesis. Tissue Engineering Part A. 2590-2603.
  • Vis forfatter(e) 2014. Age-Related Dysfunction in Mechanotransduction Impairs Differentiation of Human Mammary Epithelial Progenitors. Cell reports. 1926-1939.
  • Vis forfatter(e) 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLOS ONE. 12 sider.
  • Vis forfatter(e) 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • Vis forfatter(e) 2013. Evaluating extracellular matrix influence on adherent cell signaling by cold trypsin phosphorylation-specific flow cytometry. BMC Cell Biology. 7 sider.
  • Vis forfatter(e) 2013. Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Research & Therapy. 10 sider.
  • Vis forfatter(e) 2013. Domains I and IV of annexin A2 affect the formation and integrity of in vitro capillary-like networks. PLOS ONE. 12 sider.
  • Vis forfatter(e) 2013. Contextual compound screening for improved therapeutic discovery. ChemBioChem. 2512-2518.
  • Vis forfatter(e) 2013. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2443-2452.
  • Vis forfatter(e) 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Vis forfatter(e) 2012. Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. European Journal of Haematology. 478-490.
  • Vis forfatter(e) 2012. S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncology. 219-225.
  • Vis forfatter(e) 2012. Osteogenic stimulatory conditions enhance growth and maturation of endothelial cell microvascular networks in culture with mesenchymal stem cells. Journal of Tissue Engineering.
  • Vis forfatter(e) 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • Vis forfatter(e) 2012. Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation. ChemMedChem. 2134-2143.
  • Vis forfatter(e) 2012. A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. Bioorganic & Medicinal Chemistry Letters. 5579-5583.
  • Vis forfatter(e) 2011. Vimentin regulates EMT induction by Slug and oncogenic H-ras and migration by governing Axl expression in breast cancer. Oncogene. 1436-1448.
  • Vis forfatter(e) 2011. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 1167-1170.
  • Vis forfatter(e) 2011. Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine. E52-E62.
  • Vis forfatter(e) 2011. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathology and Applied Neurobiology. 189-205.
  • Vis forfatter(e) 2010. Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Bioorganic & Medicinal Chemistry. 8660-8668.
  • Vis forfatter(e) 2010. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcyclic acid lactone series and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 1167-1170.
  • Vis forfatter(e) 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Vis forfatter(e) 2010. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry. 41-51.
  • Vis forfatter(e) 2009. Mural cell associated VEGF is required for organotypic vessel formation. PLOS ONE.
  • Vis forfatter(e) 2009. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 3439-3447.
  • Vis forfatter(e) 2009. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry Part A. 41-51.
  • Vis forfatter(e) 2008. Enhanced gene expression from retroviral vectors. BMC Biotechnology. 6 sider.
  • Vis forfatter(e) 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Vis forfatter(e) 2007. Target discovery using retroviruses. Expert Opinion on Drug Discovery. 1285-1300.
  • Vis forfatter(e) 2007. RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. International Journal of Cancer. 961-969.
  • Vis forfatter(e) 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • Vis forfatter(e) 2007. Expanding the spectrum of genetic elements transferable by retroviral vectors. DNA and Cell Biology. 773-779.
  • Vis forfatter(e) 2004. Stable, stoichiometric delivery of diverse protein functions. Journal of Biochemical and Biophysical Methods. 101-110.
  • Vis forfatter(e) 2004. Isolation of Genetic Effectors using the Tetracycline-Regulatable System. Genomu Igaku : Genome Medicine.
  • Vis forfatter(e) 1999. Salmon eggshell protein expression: A marker for environmental estrogens. Marine Biotechnology. 252-260.
  • Vis forfatter(e) 1999. Salmon Eggshell Protein Expression: A Marker for Environmental Estrogens. Marine Biotechnology. 252-260.
  • Vis forfatter(e) 1995. Embryonic expression and DNA-binding properties of zebrafish pax-6. Biochemical and Biophysical Research Communications - BBRC. 122-128.
  • Vis forfatter(e) 1993. Expression of growth hormone genes in Atlantic salmon. Journal of Molecular Endocrinology. 167-179.
  • Vis forfatter(e) 1993. Biotechnology in Aquaculture, with Special Reference to Transgenic Salmon. Biotechnology & Genetic Engineering Reviews. 31-56.
  • Vis forfatter(e) 1992. The complete nucleotide sequence of the Atlantic salmon growth hormone I gene. Biochimica et Biophysica Acta. 345-348.
Vitenskapelig foredrag
  • Vis forfatter(e) 2013. Prevascularization of tissue-engineered constructs with endothelial and mesenchymal stem cells.
Mastergradsoppgave
  • Vis forfatter(e) 2019. The Role of Axl in Cancer and Stem Cell Plasticity: in vivo Lineage Tracing and Imaging Mass Cytometry Analysis.
  • Vis forfatter(e) 2018. Investigating the role of vitamin K in Axl-mediated melanoma progression and chemotherapeutic resistance.
  • Vis forfatter(e) 2017. Axl Inhibition Enhances Sensitivity of BRAF Mutant Melanoma Cells to Vemurafenib.
  • Vis forfatter(e) 2015. The role of Axl in melanoma metastasis.
  • Vis forfatter(e) 2013. Metabolic reprogramming in Slug and Twist overexpressing MCF10A cells.
  • Vis forfatter(e) 2013. In vitro phenotypic patterning of vascular cells by nano- and micro-design of the matrix substatum.
  • Vis forfatter(e) 2012. A study of mitochondrial function, ROS and signaling in Twist overexpressing cells.
  • Vis forfatter(e) 2010. Effekten av arakidonsyremetabolitten prostaglandin E2 (PGE2) på humane endotelceller.
  • Vis forfatter(e) 2008. The disruption of VEGF signalling by the inhibition of delta 5- fatty acid desaturase (dFADS) in HUVECs.
  • Vis forfatter(e) 2008. Assessing Blood Vessel Formation and Maturation in Tissue Engineering Implants -The Role of Akt Kinase.
  • Vis forfatter(e) 2006. Knockdown of p110β subunit of phosphatidylinositol 3-kinase in human umbilical vein endothelial cells with small interfering RNA.
Brev til redaktøren
  • Vis forfatter(e) 2018. In reply. JAMA Internal Medicine. 585-586.
Doktorgradsavhandling
  • Vis forfatter(e) 2019. The role of AXL and the microenvironment in cancer cell plasticity and therapy responses. A study in non-small cell lung cancer models.
  • Vis forfatter(e) 2019. The receptor tyrosine kinase AXL in tumor phenotypic plasticity and acquired resistance to cancer targeted- and immunotherapy.
  • Vis forfatter(e) 2018. The effects of ageing on microenvironment-contextual epithelial cell signalling .
  • Vis forfatter(e) 2017. Mechanisms of AXL Mediated Cell Plasticity and Drug Resistance .
  • Vis forfatter(e) 2017. Investigations of the cancer therapeutic and protective effects of warfarin-mediated inhibition of the receptor tyrosine kinase AXL.
  • Vis forfatter(e) 2016. The Role of Age in Cellular Responses to Microenvironmental Cues as a Breast Cancer Susceptibility Factor.
  • Vis forfatter(e) 2015. The role of Axl signaling in phenotypic plasticity in normal and neoplastic epithelial cells.
  • Vis forfatter(e) 1993. Molecular studies on the gene structure and expression of Atlantic salmon growth hormone. (dr.scient).
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) 2020. Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. 22 sider.
  • Vis forfatter(e) 2017. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 28 sider.
  • Vis forfatter(e) 2013. The Tumor Microenvironment as a Transient Niche: A Modulator of Epigenetic States and Stem Cell Funct. 16 sider.
  • Vis forfatter(e) 2013. Image-based high-throughput screening for inhibitors of angiogenesis. 13 sider.
  • Vis forfatter(e) 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. 13 sider.
  • Vis forfatter(e) 1993. Cloning and characterization of growth regulating genes from Atlantic salmon: A strategy for increasing growth rate by microinjection of a modified growth hormone gene into fertilized salmon eggs. 7 sider.
Sammendrag/abstract
  • Vis forfatter(e) 2018. Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
  • Vis forfatter(e) 2013. Warfarin blocks Gas6-mediated Axl activation required for pancreatic tumor EMT and metastasis. Annals of Surgical Oncology. S133-S133.
  • Vis forfatter(e) 2013. Axl, a therapeutic target in AML mediates stroma-induced chemoresistance. Onkologie (Basel). 44-44.
  • Vis forfatter(e) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Vis forfatter(e) 2009. The receptor tyrosine kinase Axl controls breast carcinoma cell invasiveness and tumor formation by regulating E-cadherin. Clinical and Experimental Metastasis. 863-863.
  • Vis forfatter(e) 2009. CARFILZOMIB: A SELECTIVE INHIBITOR OF THE CHYMOTRYPSIN-LIKE ACTIVITY OF THE CONSTITUTIVE PROTESOME AND IMMUNOPROTEASOME HAS ANTI-TUMOR ACTIVITY ON MULTIPLE MYELOMA, LYMPHOMA AND LEUKEMIA CELLS WITH MINIMAL EFFECTS ON NORMAL CELLS. Haematologica. 148-149.
  • Vis forfatter(e) 2008. The scaffold protein RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. The FEBS Journal. 315-315.
  • Vis forfatter(e) 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
Poster
  • Vis forfatter(e) 2013. Endothelial Microvascular Networks Influence Gene Expression Profiles in MSCs.
  • Vis forfatter(e) 2012. Osteogenic conditions stimulate microvascular networks – establishing culture conditions for stem cell based reconstruction of bone defects.
  • Vis forfatter(e) 2008. Co-culuture of endothelial cells and mesenchymal stem cells on 3D scaffolds.
  • Vis forfatter(e) 2007. Development of a near infrared reporter system for in vivo imaging.
  • Vis forfatter(e) 2007. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Errata
  • Vis forfatter(e) 2016. Corrigendum: A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2020. Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. Cancer Drug Resistance. 22 sider.
  • Vis forfatter(e) 2017. Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm. 53-66.
  • Vis forfatter(e) 2014. Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics. Advanced Drug Delivery Reviews. 123-131.
  • Vis forfatter(e) 2010. Image-based high-throughput screening for anti-angiogenic drug discovery. Current pharmaceutical design. 3958-3963.
  • Vis forfatter(e) 2010. High content screening: seeing is believing. Trends in Biotechnology. 237-245.
  • Vis forfatter(e) 2007. RNAi screening for therapeutic targets in human malignancies. Current Pharmaceutical Biotechnology. 337-343.
  • Vis forfatter(e) 2007. MicroRNAs in tumorigenesis. Current Pharmaceutical Biotechnology. 320-325.

Se fullstendig oversikt over publikasjoner i CRIStin.

Prof. Lorens completed undergraduate studies at Carleton College (USA) and University of Bergen (UiB), and graduate studies in chemistry (MS) and molecular biology (PhD) at UiB in 1993. He did postdoctoral work with Prof. Garry Nolan at Stanford University studying tumor and immune cell apoptosis mechanisms, before joining Rigel Pharmaceuticals in 1997. As one of the first scientists at Rigel, Prof. Lorens led technology development and was later Director of Oncology R&D. He returned to UiB as a Professor in the Medical Faculty, starting his academic laboratory in the Dept. Biomedicine in 2004 to focus on cancer research. Prof. Lorens is a principal investigator at the Center for Cancer Biomarkers, Norwegian Center of Excellence. He founded BerGenBio AS in 2008 to facilitate clinical translation of his group’s pioneering research on the Axl receptor tyrosine kinase. He continues to serve as Chief Scientific Officer. BerGenBio’s Axl inhibitor (BGB324) is currently in Phase I/II clinical trials to treat cancer.

In addition to his university research, teaching and supervisory activities, Prof. Lorens serves on the Editorial Board of Cancer Research and is an Affiliate at Lawrence Berkeley National Laboratory (USA). He has held several research administration and scientific advisory positions, including a current appointment to the board of the Research Council Division of Innovation. He has received several awards recognizing his achievements in innovation and holds several patents. A full bibliography is available here

Forskergrupper